Interim report for the nine months ended September 30,

Summary: For the first nine months of 2008 the Pharmexa Group generated
revenues and other operating income of DKK 16,138 thousand and a net loss of
DKK 117,095 thousand. Research and development costs totalled DKK 116,307
thousand. The Pharmexa Group retains its financial forecast for the full year.

Interim report for the nine months ended September 30, 2008

Attachments